Assessing the Generalizability of the Tachidino Protocol to Different Clinical Contexts
Launched by IRCCS EUGENIO MEDEA · May 8, 2020
Trial Information
Current as of May 06, 2025
Unknown status
Keywords
ClinConnect Summary
Specifically, the intervention system based on the web platform "Tachidino" and routinely used for the rehabilitation of reading and spelling disorders at Medea, Lombardy region, would be extended to Marche (precisely, the clinical service connected to Urbino University, located in Pesaro, a coastal town in Central Italy), a different geographical region with different population characteristics. Precisely, the Lombardy region is a highly industrialized region with the highest digitalization rate in Italy, whereas Marche is a more agriculture-oriented region, with lower population density a...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A formal diagnosis of Developmental Dyslexia, Specific Reading Disorders, or Mixed Scholastic Learning Disorders
- • Age between 7 and 16
- • Attending at least the third class of primary school
- • Monolingual speakers of Italian or bilingual speakers with perfect mastery of the Italian language (equivalent to monolinguals)
- • Intelligence Quotient (IQ) \>= 80
- • At least one z-score below -2 Standard Deviations from age mean in at least one of the following tests: text reading, word reading, nonword reading ("DDE-2" battery, "MT" tests)
- • Not having received any specific rehabilitation treatment for dyslexia before
- Exclusion Criteria:
- • Intellectual disability
- • Neurological disorders
- • Sensory deficits that are not /cannot be corrected-to-normal by lenses or hearing aids.
About Irccs Eugenio Medea
IRCCS Eugenio Medea is a leading clinical research institute based in Italy, dedicated to advancing pediatric healthcare through innovative research and evidence-based practices. As a recognized center of excellence, it focuses on multidisciplinary approaches to address complex health challenges in children and adolescents, particularly in the fields of neurodevelopmental disorders, mental health, and rehabilitation. The institute collaborates with national and international partners to conduct rigorous clinical trials, aiming to translate scientific discoveries into effective therapeutic interventions. Committed to enhancing patient outcomes, IRCCS Eugenio Medea prioritizes ethical standards and patient safety in all its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bosisio Parini, Lc, Italy
Pesaro, , Italy
Urbino, , Italy
Patients applied
Trial Officials
Maria L Lorusso, Ph.D.
Principal Investigator
IRCCS E. Medea
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials